Compare Crispr Therapeutics AG (CRSP) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Value Index Fund ETF — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Vanguard Value Index Fund ETF trades at $220.6 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 53.8× Crispr Therapeutics AG's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| CRSP | VTV | |
|---|---|---|
Market Cap | $4.88B | $262.40B |
Volume | 2,861,747 | 3,293,281 |
Sector | Health | — |
52-Week High | $74.92 | $227.51 |
52-Week Low | $44.34 | $182.86 |
Typical Hold Time | 77 Days | 142 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
VTV trades at $220.59, up 1.09% today, with a bearish technical signal overall despite bullish moving averages. The ETF offers a 2.3% dividend yield and has attracted institutional buying, as seen with QRG Capital Management increasing its stake by 14.7% in Q3 2026. Recent news highlights value stocks outperforming growth in 2026, with VTV leading among Vanguard's large-cap offerings.
The outlook for VTV is supported by the rotation into value stocks and its low 0.03% fee, but risks include underperformance versus the S&P 500 over the long term and sensitivity to interest rate changes. Investor sentiment is mixed, balancing value's resurgence against broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
